US · LMNX
Luminex Corporation
- Sector
- Healthcare · Medical - Instruments & Supplies
- Headquarters
- Austin, TX 78727
- Website
- luminexcorp.com
Price · as of 2020-12-31
$13.68
Market cap 0
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | $4.98 | -63.61% |
| Graham Formula(GF) | $10.55 | -22.92% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2006 | $1.96 | $1.54 | |||
| 2007 | $1.46 | $0.00 | |||
| 2008 | $4.50 | $3.68 | |||
| 2009 | $6.60 | $10.08 | |||
| 2010 | $5.33 | $3.16 | |||
| 2011 | $6.80 | $12.98 | |||
| 2012 | $6.61 | $5.31 | |||
| 2013 | $6.24 | $2.31 | |||
| 2014 | $11.20 | $13.39 | |||
| 2015 | $11.96 | $11.14 | |||
| 2016 | $9.09 | $6.92 | |||
| 2017 | $8.81 | $14.15 | |||
| 2018 | $6.37 | $4.60 | |||
| 2019 | $3.29 | $0.00 | |||
| 2020 | $4.98 | $10.55 |
AI valuation
Our deep-learning model estimates Luminex Corporation's (LMNX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $13.68
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
$4.98
-63.61% upside
Graham Formula
$10.55
-22.92% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| LMNX | Luminex Corporation | $13.68 | 0 | — | — | -64% | -23% | — | — | — | — | — | — | 59.38% | 10.17% | 3.63% | 3.09% | 10.04% | 2.31% | 0.40 | 3.56 | 5.82 | 4.30 | -2.29 | -47975.00% | 2473.00% | -126355.00% | — | 0.57 | 7.58% | — | 108.70% | — | — | — | — | — |
| ATRC | AtriCure, Inc. | $32.32 | 1.61B | +44% | -34% | -90% | — | -129.01 | 3.00 | 2.76 | 86.02 | — | 7.06 | 74.41% | -0.64% | -2.14% | -2.40% | -0.83% | -1.81% | 0.18 | -0.59 | 3.96 | 2.87 | -4.89 | -7474.00% | 1488.00% | -52900.00% | 3.27% | 0.70 | 11.67% | 0.00% | 0.00% | 3.01% | -405.42 | 28.94 | 2.61 | 5.82 |
| AUPH | Aurinia Pharmaceuticals I… | $14.45 | 1.9B | +200% | +441% | +4% | +309% | 6.65 | 3.28 | 6.75 | 12.42 | 0.13 | 3.31 | 88.46% | 37.06% | 101.47% | 59.91% | 58.85% | 44.11% | 0.13 | 24.23 | 5.25 | 4.69 | -0.04 | 516718.00% | 2038.00% | 20699.00% | 7.09% | 1.45 | 75.96% | 0.00% | 0.00% | 5.21% | 15.12 | 11.71 | 5.60 | 6.99 |
| AZTA | Azenta, Inc. | $30.54 | 1.4B | +43% | -48% | -47% | — | -28.75 | 0.93 | 2.70 | 25.40 | — | 1.74 | 45.52% | -1.90% | -9.39% | -3.19% | -0.31% | -2.68% | 0.06 | — | 2.98 | 2.23 | -3.12 | -6052.00% | 355.00% | 21029.00% | 2.39% | 0.30 | 2.67% | 0.00% | 0.00% | 0.00% | -121.90 | 35.84 | 2.31 | 4.42 |
| GRDN | Guardian Pharmacy Service… | $28.99 | 1.84B | +3% | +293% | — | — | -16.12 | 8.03 | 0.93 | -27.12 | — | 19.59 | 19.89% | -5.12% | -7.11% | -83.14% | -46.27% | -24.00% | 0.26 | -19.19 | 1.05 | 0.71 | -0.75 | -55385.00% | 1742.00% | -2608.00% | 3.63% | 0.40 | 30.59% | 3.12% | -50.30% | 11.06% | -18.72 | 28.32 | 0.96 | 7.31 |
| KMTS | KESTRA MEDICAL TECHNOLOGI… | $26.50 | 1.36B | +47% | +236% | — | — | -6.49 | 3.60 | 12.35 | -5.57 | -4.28 | 3.60 | 40.47% | -177.85% | -190.28% | 5732.26% | 132.69% | -66.62% | 0.22 | -13.75 | 6.72 | 6.47 | 1.97 | 15147.00% | 11505.00% | 1941.00% | -13.70% | -2.04 | 126.23% | 0.22% | -1.50% | 31.39% | -5.13 | -5.39 | 9.12 | 2.34 |
| LMAT | LeMaitre Vascular, Inc. | $86.27 | 1.95B | -32% | -38% | -86% | -52% | 41.10 | 5.37 | 8.23 | 25.41 | 93.35 | 7.69 | 68.63% | 23.77% | 20.03% | 13.87% | 18.60% | 9.80% | 0.55 | 254.91 | 13.14 | 10.77 | 2.40 | 4403.00% | 1363.00% | 2603.00% | 2.05% | 1.44 | 17.08% | 0.79% | 32.60% | 0.79% | 32.46 | 45.64 | 7.71 | 6.95 |
| OGN | Organon & Co. | $6.38 | 1.66B | +645% | -40% | — | -41% | 9.98 | 2.48 | 0.30 | 7.87 | — | -0.41 | 54.09% | 20.67% | 3.01% | 30.56% | 6.35% | 1.44% | 11.70 | 2.55 | 1.82 | 0.84 | 6.41 | -7838.00% | -292.00% | -850.00% | 28.84% | 0.29 | 6.04% | 4.72% | 47.10% | 11.95% | 7.85 | 18.76 | 1.62 | 1.09 |
| PAHC | Phibro Animal Health Corp… | $41.15 | 1.67B | +57% | +183% | -89% | -1% | 32.91 | 5.56 | 1.23 | 15.48 | 1.75 | 8.38 | 30.85% | 8.52% | 3.72% | 17.80% | 9.58% | 4.12% | 2.67 | 3.32 | 2.76 | 1.04 | 4.72 | 188333.00% | 2737.00% | -976.00% | 2.63% | 0.27 | 5.11% | 1.22% | 40.30% | 1.22% | 20.57 | 54.33 | 1.75 | 2.84 |
| QDEL | QuidelOrtho Corporation | $27.37 | 1.86B | -22% | -67% | — | — | -1.35 | 0.80 | 0.56 | -8.47 | — | -2.38 | 46.67% | -33.67% | -41.45% | -46.15% | -18.22% | -18.56% | 1.46 | -5.18 | 1.50 | 0.64 | -5.40 | -4535.00% | -189.00% | -2596.00% | -5.42% | 0.11 | -1.65% | 0.00% | 0.00% | 0.00% | -4.50 | -49.82 | 1.51 | 0.29 |
| TXG | 10x Genomics, Inc. | $13.49 | 1.68B | +312% | -24% | -66% | — | -66.29 | 3.63 | 4.49 | -22.74 | — | 3.96 | 69.05% | -17.25% | -6.77% | -5.78% | -26.72% | -4.44% | 0.20 | — | 4.46 | 3.95 | 2.85 | -7697.00% | 525.00% | -237116.00% | 4.51% | 0.89 | 31.35% | 0.00% | 0.00% | 1.90% | -22.74 | 19.38 | 3.92 | 5.92 |
About Luminex Corporation
Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market; FlowSight Imaging Flow cytometer; ImageStream System; CellStream Flow Cytometer; Guava easyCyte line; and Muse Cell Analyzer. The company also provides MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; SYNCT data management software solutions; TDAS, an analysis program designed for development and optimization of nucleic acid assays; IDEAS, an image analysis software; and xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism. In addition, it offers MultiCode assays and products comprising HSV 1&2 assays, and other products to detect infectious agents in clinical samples; ARIES cassettes that are self-contained assay consumables, such as ARIES HSV 1&2 assays, ARIES FLU A/B and RSV assays, ARIES group A strep assays, ARIES bordetella assays, ARIES GBS assay, and ARIES C. difficile assays; and VERIGENE test cartridges. The company serves pharmaceutical companies, clinical laboratories, and research and medical institutions. Luminex Corporation was founded in 1995 and is based in Austin, Texas.
- CEO
- Nachum Shamir
- Employees
- 1.33K
- Beta
- 0.57
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $13.68) − 1 = — (DCF, example).